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S U M M A R Y
Objectives: The immunogenicity and safety of the tetravalent meningococcal serogroups A, C, W-135,
and Y tetanus toxoid conjugate vaccine (MenACWY–TT) were evaluated in subjects previously
vaccinated with a tetravalent meningococcal polysaccharide vaccine and in subjects without previous
meningococcal vaccination.
Methods: In this phase II, open, controlled study (NCT00661557), healthy subjects aged 4.5–34 years
received one dose of MenACWY–TT at month 0. Subjects in the MPS group (n = 192) had received
polysaccharide vaccine in a study conducted 30–42 months earlier; age-matched subjects in the noMPS
control group (n = 79) had received no meningococcal vaccination within the past 10 years. Serum
bactericidal activity using rabbit complement (rSBA) was measured at month 0 and month 1.
Results: At month 1, 97.0% of subjects had rSBA titers 1:128. Post-vaccination rSBA geometric mean
titers (GMTs) were 3.9-fold higher than pre-vaccination in both treatment groups. Exploratory
analyses showed no statistically signiﬁcant differences between groups in percentages of subjects with
rSBA titers 1:8 and 1:128, but signiﬁcantly lower rSBA GMTs and vaccine response rates for each
serogroup in the MPS versus the noMPS group. MenACWY–TT had an acceptable safety proﬁle in both
groups.
Conclusions: These results suggest that MenACWY–TT could be used in vaccination programs
irrespective of the pre-vaccination status with polysaccharide vaccine.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Neisseria meningitidis remains a major cause of invasive
meningococcal disease and is responsible for at least 500 000
cases and 50 000 deaths each year.1 N. meningitidis has been
classiﬁed into 13 serogroups according to differences in capsular
polysaccharides, of which serogroups A, B, C, W-135, and Y are
responsible for most meningococcal disease cases.2 The geographic
distribution of the different serogroups differs and their epidemic
capabilities are unpredictable.2 Serogroups B and C are responsible
for the majority of meningococcal disease cases in the USA and in
Europe. Also, serogroup Y emerged as an important cause of
meningococcal disease in the USA in the 1990s,2 and this serogroup* Corresponding author. Tel.: +961 1 350000; fax: +961 1 370781.
E-mail address: gdbaibo@aub.edu.lb (G. Dbaibo).
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http://dx.doi.org/10.1016/j.ijid.2012.04.006appears to be emerging in Scandinavian countries3–5 and in the
UK.6 In Africa, Asia, and the Middle East, serogroup A is the
predominant cause of meningococcal disease, and this serogroup
has been responsible for large epidemics in the African meningitis
belt.2 Serogroup W-135 has also caused two large outbreaks, one in
Saudi Arabia during the Hajj in 2000 and the other in Burkina Faso
between 2002 and 2005.7,8
Many of the Hajj pilgrims to Saudi Arabia had been vaccinated
with a bivalent polysaccharide vaccine against serogroups A and C
before the outbreak caused by serogroup W-135 in 2000.7 In 2002,
in response to this outbreak, Saudi Arabia extended the
recommendation from vaccination with the bivalent polysaccha-
ride vaccine to vaccination with a tetravalent polysaccharide
vaccine against serogroups A, C, W-135, and Y for all pilgrims.
Indeed, vaccination remains the best strategy to prevent menin-
gococcal disease, and polysaccharide vaccines are well tolerated,
immunogenic, and provide protection for 3–5 years in adults andses. Published by Elsevier Ltd. All rights reserved.
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in the incomplete maturation of B-cells, do not induce immuno-
logic memory, do not confer herd protection, and induce
insufﬁcient responses in children younger than 2 years of age,
an age group at high risk for meningococcal infections.9,10
To overcome these limitations, capsular polysaccharides have
been covalently coupled to carrier proteins to improve their
immunogenicity and to induce a T-cell-dependent immune
response.9 Since 1999, meningococcal conjugate vaccines against
serogroup C have been available and widely used.11,12 Recently, a
new serogroup A meningococcal conjugate vaccine has been
successfully introduced in Africa.13 Presently, two tetravalent
meningococcal conjugate vaccines against serogroups A, C, W-135,
and Y are licensed in various countries.14,15 In addition, a new
tetravalent meningococcal serogroups A, C, W-135, and Y tetanus
toxoid conjugate vaccine (MenACWY–TT, NimenrixTM, Glaxo-
SmithKline Biologicals SA) is licensed for use in Europe as a single
dose in individuals from the age of 2 years, and has been shown to
elicit a good immune response and to have a clinically acceptable
safety proﬁle in toddlers, children, and young adults.16–22 One
potential advantage of conjugate vaccines over polysaccharide
vaccines is that they prime for immunologic memory, which
means that the vaccine should elicit higher responses to
subsequent doses of polysaccharide or conjugate vaccines.9,23 In
contrast, polysaccharide vaccines may induce hyporesponsiveness
to subsequent vaccination, in particular for serogroup C, although
the clinical relevance of this phenomenon is unknown.9,24–26
The purpose of this study was to evaluate the safety and
immune response induced by one dose of MenACWY–TT when
given approximately 3 years after administration of a licensed
tetravalent meningococcal plain polysaccharide vaccine (Men-PS).
2. Materials and methods
2.1. Study design
This was a phase II, open, controlled, single-center study
(NCT00661557) conducted in Lebanon between May and Decem-
ber 2008, which was an extension of a previous trial
(NCT00227422). Subjects were divided into three age strata:
4.5–10 years, 11–17 years, and 18–34 years of age at the time of
vaccination in the present study. Within each age stratum, subjects
were assigned 3:1 to two parallel vaccine groups: the MPS group
included subjects who had received one dose of Men-PS in the
study conducted 30–42 months earlier (NCT00227422) and the
noMPS group included age-matched subjects who had not received
any meningococcal vaccine within the past 10 years. The previous
study was conducted in 2005 and was designed to evaluate the
immunogenicity and safety of the Men-PS vaccine. In the present
study, one dose of MenACWY–TT was administered to all the
subjects in the MPS and the noMPS groups. Two blood samples
were collected from all subjects for the analysis of the immune
response to the MenACWY–TT vaccine, one prior to conjugate
vaccination (month 0) and one at 1 month after conjugate
vaccination (month 1). To determine safety, the patients were
followed-up for 6 months after vaccination.
The study was conducted in accordance with good clinical
practice guidelines and all applicable regulatory requirements,
including the Declaration of Helsinki. Written informed consent
was obtained from every subject, or in the case of participating
minors, from their parents/guardians, prior to the performance of
any study-speciﬁc procedures. In addition to the consent provided
by their parents/guardians, all subjects aged 7 years and above also
provided informed assent. The study protocol and the informed
consent and assent were reviewed and approved by an institu-
tional review board in Lebanon (Faculty of Medicine, AmericanUniversity of Beirut). This study has been registered at www.cli-
nicaltrials.gov (NCT00661557).
2.2. Study objectives
The primary objective of this study was to evaluate the
immunogenicity of the MenACWY–TT vaccine in terms of rSBA
titers (serum bactericidal assay using rabbit complement) against
each serogroup at 1 month post-vaccination in subjects who had
either received one dose of the Men-PS vaccine between 30 and 42
months earlier or had not received any meningococcal vaccine
within the past 10 years.
The secondary objectives of the study included the evaluation of
the immunogenicity in terms of anti-PS and anti-TT antibody
concentrations prior to and after MenACWY–TT vaccination and of
the safety proﬁle of the MenACWY–TT vaccine in subjects enrolled
in the MPS and the noMPS groups.
2.3. Study subjects
Subjects were healthy males and females aged 4.5 to 34 years at
the time of the MenACWY–TT vaccination, who had previously
completed childhood vaccinations to the best of subject/parent/
guardian knowledge. Subjects in the MPS group had received one
dose of the Men-PS vaccine in a previous study, approximately 3
years earlier, and had not received any further meningococcal
vaccine after completion of the previous study. Subjects in the
noMPS group had not been vaccinated against meningococcal
disease of any serogroup in the last 10 years.
Subjects were ineligible to participate in the study if they were
immunosuppressed from any cause, had previously been vacci-
nated with a conjugate meningococcal vaccine at any time, or had
received vaccination against tetanus within 30 days prior to
administration of the study vaccine. Subjects with a history of
meningococcal disease, chronic alcohol consumption, or drug
abuse were also excluded. Moreover, subjects were ineligible if
they had received immunoglobulins or blood products in the
preceding 3 months, had a major congenital defect, serious illness,
neurological or seizure disorder, or acute disease at the time of
enrolment. Females of childbearing age were required to practice
adequate contraception for 30 days prior to vaccination, have a
negative pregnancy test at the time of vaccination, and to continue
contraceptive precautions for 2 months after vaccination.
2.4. Vaccines
One dose of the MenACWY–TT vaccine (NimenrixTM, Glaxo-
SmithKline Biologicals SA, Rixensart, Belgium) contained 5 mg of
each of the meningococcal serogroups A, C, W-135, and Y
polysaccharides, conjugated to TT (44 mg), and was supplied
as a lyophilized pellet in a monodose vial for delivery of 0.5 ml after
reconstitution with saline diluent. A single MenACWY–TT vaccine
dose was administered intramuscularly in the non-dominant
deltoid of all subjects.
In the previous study, subjects from the MPS group received one
subcutaneous dose of the Men-PS vaccine (Mencevax1 ACWY, GSK
Biologicals, SA), which contained 50 mg of each of the meningo-
coccal serogroups A, C, W-135, and Y polysaccharides.
2.5. Immunogenicity assessment
Immunogenicity was assessed by functional antibody
responses against the four serogroups using a serum bactericidal
activity (SBA) assay with baby rabbit serum as complement source
(rSBA, cut-off 1:8).27 rSBA-MenC titers 1:8 are considered to
predict protection,28 and in this study, this threshold was extended
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conservative correlate of protection, were also computed.30
Vaccine response was calculated and deﬁned as an rSBA titer of
at least 1:32 at 1 month after conjugate vaccination in subjects
who were seronegative (rSBA titer <1:8) prior to conjugate
vaccination, and as at least a four-fold increase in titer from pre-
vaccination to 1 month post-vaccination in subjects who were
seropositive prior to conjugate vaccination.
Antibody concentrations against meningococcal polysacchar-
ides of all serogroups (anti-PS, cut-off 0.30 mg/ml)31 and against TT
(anti-TT, cut-off 0.10 IU/ml)32 were determined by ELISA. The
percentages of subjects with anti-PS concentrations 2.0 mg/ml as
well as with anti-TT concentrations 1.0 IU/ml were also
computed. Subjects from each group were sub-randomized into
two subsets of 50% of the subjects to be tested for anti-PS antibody
concentrations against either serogroups A and C or serogroups W-
135 and Y. All the blood samples were tested at the central
laboratories of GSK Biologicals.
2.6. Safety and reactogenicity assessment
Solicited local (pain, redness, and swelling) and general (fatigue,
fever, gastrointestinal symptoms, and headache) adverse events
(AEs) were recorded during a 4-day (days 0–3) follow-up period,
while unsolicited AEs were recorded during a 31-day (days 0–30)
follow-up period after MenACWY–TT administration. Symptom
intensity was graded on a 0–3 scale, where symptoms of grade 3
intensity were deﬁned as follows: site redness or swelling
>50 mm, fever >39.5 8C, and all other AEs that prevented normal
activities. The occurrence of new onset chronic illnesses (NOCIs)
and serious adverse events (SAEs) were reported through 6 months
after the vaccination. All solicited local AEs reported during the 4-
day follow-up period were automatically considered to be related
to vaccination. The relationship between vaccination and all other
AEs was assessed by the investigator.Figure 1. Number of enrolled subjects in each treatment group and reasons for eliminat
study (NCT00227422); noMPS = subjects with no meningococcal vaccination within
n = number of subjects).2.7. Statistical analyses
With 322 subjects from the previous study eligible to be
enrolled in the MPS group and the 3:1 group ratio design, a sample
size of 430 subjects was anticipated. It was expected that only a
third of the subjects from the previous study would provide
consent for the study and that 15% of enrolled subjects would be
non-evaluable for the immunogenicity analysis. Hence 183
subjects were estimated in the MPS group and 61 in the noMPS
group. A listing of subjects who were willing to participate was
provided by the investigator. In order to ensure group compara-
bility in age, this listing was used to select age-matched subjects
for enrollment in the noMPS group.
The total vaccinated cohort (TVC) included all vaccinated
subjects and was the primary cohort for the analysis of safety.
Analysis of the solicited symptoms only included vaccinated
subjects for doses with documented safety data (i.e. symptom
sheet completed), for other safety analyses all vaccinated subjects
were considered. The analyses of immunogenicity were performed
on the according-to-protocol (ATP) cohort for immunogenicity,
which included subjects who met all eligibility criteria and met no
elimination criteria during the study, and for whom immunoge-
nicity data for at least one antigen were available at month 1.
The percentages of participants with antibody titers or
concentrations above the proposed cut-offs and of those with a
vaccine response, as well as geometric mean antibody concentra-
tions/titers (GMC/T) were calculated with exact 95% conﬁdence
intervals (95% CI) in each treatment group. Two groups were
considered signiﬁcantly different if the asymptotic standardized
two-sided 95% CI for the difference between groups in percentages
of participants with titers/concentrations above proposed cut-offs
or with a vaccine response did not contain the value ‘0’, or if the
95% CI for the GMT/GMC ratio between groups did not contain the
value ‘1’ (exploratory analyses). The GMT/GMC ratios were
computed by an analysis of covariance model on the log10ions from the study cohorts (MPS = subjects vaccinated with Men-PS in a previous
 the past 10 years; TVC = total vaccinated cohort; ATP = according-to-protocol;
Table 1
Percentages of subjects with rSBA titers equal to or above cut-off values, and rSBA geometric mean titers (ATP cohort for immunogenicity)
Antibody Groupa Timingb nc % 1:8 (95% CI)d % 1:128 (95% CI)d GMT (95% CI)e
rSBA-MenA MPS Month 0 160 100 (97.7–100) 100 (97.7–100) 1770.1 (1569.0–1996.9)
Month 1 146 100 (97.5–100) 100 (97.5–100) 6868.8f (6044.9–7805.0)
noMPS Month 0 71 98.6 (92.4–100) 98.6 (92.4–100) 1103.8 (863.2–1411.5)
Month 1 69 100 (94.8–100) 100 (94.8–100) 13014.9 (10722.2–15798.0)
rSBA-MenC MPS Month 0 165 75.2 (67.8–81.5) 59.4 (51.5–67.0) 116.6 (80.2–169.4)
Month 1 169 100 (97.8–100) 97.0 (93.2–99.0) 1945.8f (1583.3–2391.1)
noMPS Month 0 70 47.1 (35.1–59.4) 37.1 (25.9–49.5) 30.1 (17.4–52.0)
Month 1 75 100 (95.2–100) 100 (95.2–100) 5494.6 (4266.3–7076.5)
rSBA-MenW-135 MPS Month 0 165 81.8 (75.1–87.4) 70.3 (62.7–77.2) 154.0 (114.0–208.1)
Month 1 169 100 (97.8–100) 100 (97.8–100) 4635.7f (3942.5–5450.7)
noMPS Month 0 74 56.8 (44.7–68.2) 32.4 (22.0–44.3) 36.9 (22.7–59.9)
Month 1 75 100 (95.2–100) 100 (95.2–100) 9078.0 (7087.7–11627.1)
rSBA-MenY MPS Month 0 167 94.6 (90.0–97.5) 89.8 (84.2–94.0) 555.2 (434.8–708.9)
Month 1 169 100 (97.8–100) 100 (97.8–100) 7799.9f (6682.8–9103.6)
noMPS Month 0 74 81.1 (70.3–89.3) 74.3 (62.8–83.8) 170.1 (106.1–272.9)
Month 1 75 100 (95.2–100) 100 (95.2–100) 13895.5 (11186.2–17260.9)
rSBA, serum bactericidal activity using rabbit complement; ATP, according-to-protocol; 95% CI, 95% conﬁdence interval.
a MPS = subjects vaccinated with Men–PS in a previous study (NCT00227422); noMPS = subjects with no meningococcal vaccination within the past 10 years.
b Month 0 = pre-vaccination blood sample; Month 1 = blood sample taken at 1 month post-vaccination.
c n = number of subjects with available results.
d % = percentage of subjects with titer within the speciﬁed range.
e GMT = geometric mean antibody titer calculated on all subjects.
f Statistically signiﬁcant lower value in the MPS group than in the noMPS group in an exploratory analysis.
Table 2
Percentages of subjects with rSBA vaccine response at 1 month post-vaccination
(ATP immunogenicity cohort)
Antibody Groupa nb % Vaccine response (95% CI)c
rSBA-MenA MPS 141 41.1d (32.9–49.7)
noMPS 65 76.9 (64.8–86.5)
rSBA-MenC MPS 165 66.7d (58.9–73.8)
noMPS 70 97.1 (90.1–99.7)
rSBA-MenW-135 MPS 165 83.0d (76.4–88.4)
noMPS 74 97.3 (90.6–99.7)
rSBA-MenY MPS 167 74.9d (67.6–81.2)
noMPS 74 95.9 (88.6–99.2)
rSBA, serum bactericidal activity using rabbit complement; ATP, according-to-
protocol; 95% CI, 95% conﬁdence interval.
a MPS = subjects vaccinated with Men–PS in a previous study (NCT00227422);
noMPS = subjects with no meningococcal vaccination within the past 10 years.
b n = number of subjects with pre- and post-vaccination results available.
c % Vaccine response = percentage of subjects showing a vaccine response deﬁned
as follows: (1) for initially seronegative subjects: antibody titer 1:32 at 1 month
post-vaccination; (2) for initially seropositive subjects: antibody titer at 1 month
post-vaccination 4-fold the antibody titer at pre-vaccination.
d Statistically signiﬁcant lower value in the MPS group than in the noMPS group
in an exploratory analysis.
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tion log10 transformation of the titers/concentrations, the age
strata, and the vaccine group as covariates.
The incidence and intensity of each solicited and unsolicited AE
were calculated with exact 95% CI. Two-sided asymptotic
standardized tests were used to detect differences between the
two groups for each solicited symptom (percentage of subjects
with the symptom) and the associated two-sided p-values were
calculated. NOCIs and SAEs were described in detail.
The statistical analyses were performed using the SAS software
version 9.1 (SAS Institute Inc., Cary, NC, USA) and Proc StatXact 7.0.
3. Results
3.1. Study subjects
A total of 192 subjects from the previous study met the eligibility
criteria and consented to enter this study; they were vaccinated in
the MPS group (Figure 1). In the noMPS group, 79 age strata-matched
subjects were enrolled and vaccinated. Of the 271 vaccinated
participants, 262 subjects completed the visit at month 1. A total of
244 subjects were included in the ATP cohort for immunogenicity,
and no subjects discontinued the study due to AEs or SAEs.
In the TVC, the mean age of the subjects across both vaccine
groups at the time of enrolment was 14.1 years (range 4–33 years).
Almost the entire population (99.3%) was of white-Arabic/North
African heritage, with nearly equivalent proportions of males
(51.3%) and females (48.7%). The demographic characteristics of
the subjects were comparable in the two groups (data not shown).
3.2. Immunogenicity
3.2.1. Serum bactericidal activity after MenACWY–TT vaccination
The pre-vaccination rSBA GMTs were higher in the MPS group
than in the noMPS group (Table 1). The rSBA GMTs increased from
pre- to post-vaccination by 3.9- to 30.1-fold in the MPS group and
by 11.8- to 246-fold in the noMPS group. One month after the
MenACWY–TT vaccination, all the subjects in both groups were
seropositive (rSBA titer 1:8) for the four serogroups, and the
proportion of subjects with rSBA titers 1:128 ranged from 97.0%
to 100% in the MPS group and was 100% for all four serogroups inthe noMPS group. The vaccine response rates to each of the four
serogroups ranged from 41.1% to 83.0% in the MPS group and from
76.9% to 97.3% in the noMPS group (Table 2).
Exploratory analyses did not detect any statistically signiﬁcant
differences between the MPS and the noMPS groups in terms of
percentages of subjects with rSBA titers 1:8 and 1:128 at 1
month after the MenACWY–TT vaccination. However, the percen-
tages of vaccine responders and the post-vaccination rSBA GMTs
for the four serogroups were signiﬁcantly lower in the MPS group
than in the noMPS group.
3.2.2. Anti-PS antibody concentrations after MenACWY–TT
vaccination
The pre-vaccination seropositivity rates in terms of percentages
of subjects with anti-PS antibody concentrations 0.3 mg/ml were
higher in the MPS group (88.2–97.6%) than in the noMPS group
(11.4–36.8%) for the four serogroups. One month after vaccination,
the seropositivity rates increased to at least 98.8%, and anti-PS
concentrations 2.0 mg/ml were reached in 97.3% to 100% of the
Table 3
Percentages of subjects with anti-PS concentrations equal to or above cut-off values, and geometric mean concentrations (ATP cohort for immunogenicity)
Antibody Groupa Timingb nc % 0.3 mg/ml (95% CI)d % 2.0 mg/ml (95% CI)d GMC (95% CI)e
Anti-PSA MPS Month 0 82 93.9 (86.3–98.0) 84.1 (74.4–91.3) 9.38 (6.37–13.81)
Month 1 82 98.8 (93.4–100) 98.8 (93.4–100) 79.15 (57.61–108.73)
noMPS Month 0 38 36.8 (21.8–54.0) 18.4 (7.7–34.3) 0.41 (0.24–0.70)
Month 1 38 100 (90.7–100) 97.4 (86.2–99.9) 47.45 (30.48–73.85)
Anti-PSC MPS Month 0 82 97.6 (91.5–99.7) 74.4 (63.6–83.4) 6.46 (4.49–9.30)
Month 1 82 100 (95.6–100) 100 (95.6–100) 31.19f (25.34–38.39)
noMPS Month 0 38 26.3 (13.4–43.1) 15.8 (6.0–31.3) 0.31 (0.20–0.47)
Month 1 38 100 (90.7–100) 100 (90.7–100) 18.81 (12.92–27.38)
Anti-PSW-135 MPS Month 0 76 88.2 (78.7–94.4) 59.2 (47.3–70.4) 3.40 (2.20–5.26)
Month 1 85 100 (95.8–100) 98.8 (93.6–100) 25.10f (19.49–32.33)
noMPS Month 0 35 11.4 (3.2–26.7) 5.7 (0.7–19.2) 0.20 (0.14–0.29)
Month 1 37 100 (90.5–100) 97.3 (85.8–99.9) 14.67 (9.25–23.28)
Anti-PSY MPS Month 0 85 91.8 (83.8–96.6) 65.9 (54.8–75.8) 4.05 (2.83–5.81)
Month 1 86 100 (95.8–100) 98.8 (93.7–100) 29.98f (23.48–38.28)
noMPS Month 0 36 13.9 (4.7–29.5) 8.3 (1.8–22.5) 0.21 (0.15–0.29)
Month 1 37 100 (90.5–100) 97.3 (85.8–99.9) 17.58 (11.89–25.99)
anti-PS, anti-polysaccharide antibodies; ATP, according-to-protocol; 95% CI, 95% conﬁdence interval.
a MPS = subjects vaccinated with Men-PS in a previous study (NCT00227422); noMPS = subjects with no meningococcal vaccination within the past 10 years.
b Month 0 = pre-vaccination blood sample; Month 1 = blood sample taken at 1 month post-vaccination.
c n = number of subjects with available results.
d % = percentage of subjects with concentration within the speciﬁed range.
e GMC = geometric mean antibody concentration calculated on all subjects.
f Statistically signiﬁcant higher value, adjusted for age strata, in the MPS group than in the noMPS group in an exploratory analysis.
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vaccination in both groups (Table 3).
Exploratory analyses did not detect any statistically signiﬁcant
differences between the MPS and the noMPS groups in terms of
percentages of subjects with anti-PS concentrations 0.3 mg/ml
and 2.0 mg/ml at 1 month after MenACWY–TT vaccination, but in
contrast with rSBA GMTs, post-vaccination anti-PS GMCs, adjusted
for age strata, were signiﬁcantly higher in the MPS group compared
to the noMPS group for serogroups C, W-135, and Y.
3.2.3. Anti-tetanus toxoid antibody concentrations
Prior to vaccination, there was a trend for lower anti-TT GMCs in
the MPS group (0.718; 95% CI 0.561–0.919) compared to the noMPS
group (1.515; 95% CI 1.032–2.223). One month after vaccination,
seropositivity rates for anti-TT were 98.2% and 98.7% in the MPS andFigure 2. Incidence (with 95% conﬁdence interval) of solicited local and general symptom
during the 31-day follow-up period after vaccination (total vaccinated cohort) (error ba
previous study (NCT00227422); noMPS = subjects with no meningococcal vaccination w
redness or swelling >50 mm; fever >39.5 8C; all other adverse events that prevented nnoMPS groups, respectively. Exploratory analyses showed that anti-
TT GMCs, adjusted for age strata, were signiﬁcantly lower in the MPS
group (17.678; 95% CI 14.494–1.562) than in the noMPS group
(41.600; 95% CI 31.587–54.787) at month 1.
3.3. Safety
In the TVC, solicited and unsolicited AEs were reported by 111
subjects (57.8%) in the MPS group and 41 subjects (51.9%) in the
noMPS group during the 4-day post-vaccination period. Grade 3
symptoms were observed in 22 subjects (11.5%) in the MPS group
compared to three subjects (3.8%) in the noMPS group. Compliance
in returning the symptom sheets was 85.9% for subjects in the MPS
group (n = 165) and 97.5% for subjects in the noMPS group (n = 77)
for both local and general symptoms.s during the 4-day follow-up period after vaccination and of unsolicited symptoms
rs represent 95% conﬁdence intervals; MPS = subjects vaccinated with Men-PS in a
ithin the past 10 years; symptoms of grade 3 intensity were deﬁned as follow: site
ormal activities.*p-value < 0.05).
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frequently reported solicited local AE in both groups and occurred
in 84 subjects (50.9%) in the MPS group and 27 subjects (35.1%) in
the noMPS group (Figure 2). Reported rates of redness and swelling
were comparable in the MPS and noMPS groups (rates of redness
were 21.2% and 22.1%, respectively, and rates of swelling were
24.2% and 26.0%, respectively). The most common solicited general
AE in the MPS group was fatigue (59 subjects; 35.8%) and in the
noMPS group was headache (17 subjects; 22.1%). Only a small
percentage (5.5% at most) of subjects had solicited symptoms with
grade 3 intensity after vaccination in both vaccine groups. Two
subjects in the MPS group reported fever >39.5 8C, which was
considered causally related to vaccination. Pain (any and grade 3),
related fever, related headache, and fatigue (any and related) were
reported more frequently in the MPS group than in the noMPS
group (p-value < 0.05).
At least one unsolicited AE was reported within the 31-day
follow-up period after the vaccine administration by 19 subjects
(9.9%) in the MPS group and 11 subjects (13.9%) in the noMPS
group (Figure 2). Throughout the entire study, one subject in the
MPS group experienced an SAE (tendon rupture) and two subjects
in the noMPS group each reported one NOCI (seasonal allergy and
rhinitis). These events were not considered as causally related to
MenACWY–TT vaccination. No deaths occurred during the study.
4. Discussion
The primary objective of this study was to evaluate the
immunogenicity and safety of the MenACWY–TT vaccine when
given to subjects previously vaccinated with a plain polysaccharide
vaccine compared to subjects who had not received a meningo-
coccal vaccine within the past 10 years, considering previous data
on the potential hyporesponsiveness induced by meningococcal
polysaccharide vaccines when subsequent doses are given.33,34
As expected, the pre-vaccination rSBA titers and anti-PS
concentrations in the present study were higher in the subjects
who had received the Men-PS vaccine in the previous study than in
subjects without prior meningococcal polysaccharide vaccination
within the past 10 years. One month after MenACWY–TT
vaccination, rSBA GMTs had increased at least 3.9-fold, and at
least 97.0% of subjects had rSBA titers 1:128 for all serogroups in
both groups. The response in the subjects with no meningococcal
vaccination within the past 10 years was consistent with that
observed in previous studies conducted with the MenACWY–TT
vaccine given in meningococcal vaccine-naı¨ve subjects.16–22
Moreover, rSBA GMTs measured in subjects initially immunized
with the Men-PS vaccine for serogroups C, W-135, and Y were
higher than those observed in the previous study (NCT00227422)
at 1 month after administration of the Men-PS vaccine (data not
shown).
Despite the increases observed in both groups, exploratory
analyses showed that post-vaccination rSBA GMTs and vaccine
response rates for all serogroups were signiﬁcantly higher in the
subjects with no meningococcal vaccination within the past 10
years than in the subjects with previous Men-PS vaccination. These
results suggest that vaccination with a polysaccharide vaccine may
reduce the response to a subsequent dose of either polysaccharide
vaccine or conjugate vaccine.14,25,26,34 Another possibility is that
the high antibody concentrations noted prior to conjugate
vaccination in the subjects with previous Men-PS administration
may interfere with the meningococcal antigens and reduce the
response to the meningococcal vaccine.35 The lower vaccine
response rates observed in the subjects with previous meningo-
coccal vaccination may also be explained by the fact that when pre-
vaccination titers are already high, it is more difﬁcult to obtain a
four-fold rise from pre- to post-vaccination, since the absolutepost-vaccination titer required to meet the deﬁnition of vaccine
response is much higher than 1:32.36 Vaccine response rates are
used to evaluate the immunogenicity of the meningococcal
vaccines because they assess the ability of participants to respond
to the vaccine regardless of their serostatus at pre-vaccination.27,37
These ﬁndings of the present study are consistent with those of
previous studies, in which lower immune responses, when
measured by rSBA assay, to meningococcal conjugate vaccines
were observed in subjects with previous vaccination with
polysaccharide meningococcal vaccines compared with meningo-
coccal vaccine-naı¨ve subjects.14,25,26,38,39
In contrast, responses measured by ELISA were generally lower
in the subjects without meningococcal vaccination within the past
10 years compared to the subjects with previous Men-PS
vaccination. The reason for this discrepancy is not entirely
understood, though several hypotheses have been suggested.
The lower rSBA levels in subjects previously vaccinated with Men-
PS may be explained by the fact that meningococcal polysaccha-
ride vaccines induce a T-cell independent response, which leads
primarily to the development of plasma cells as compared to
memory cells. It has been suggested that upon re-exposure to
polysaccharide, the plasma cells are stimulated but not replen-
ished, resulting in an overall depletion of the memory cell pool.
Subsequent administration of a conjugate vaccine may be able to
overcome this depletion to a certain extent.34 However, the ELISA
assay only measures total antibody concentration, and does not
evaluate the functional capacity of those antibodies. Although
previous priming with polysaccharide vaccine may result in overall
higher antibody concentrations, the bactericidal activity induced
after the conjugate vaccine may be reduced.
A side observation of this study is that higher anti-TT
concentrations were observed in the group of subjects with no
previous meningococcal vaccination compared to the group of
subjects who received the Men-PS vaccine in the previous study,
both prior to vaccination and at 1 month post-vaccination with
MenACWY–TT. Post-vaccination anti-TT differences are difﬁcult to
interpret because of the possible selection bias introduced into the
study by the lack of randomization and the smaller sample size in
the control group. The difference in pre-existing TT immunity
between the two groups, also reﬂected by post-vaccination anti-TT
response, is also a confounding factor to the understanding of the
different immunogenicity results (anti-PS and rSBA) between the
two groups.
MenACWY–TT has previously been shown to be well-tolerated
in toddlers, children, and adults.16–22 In this study, a higher
incidence of some of the solicited symptoms was observed in the
subjects with prior polysaccharide vaccination. This is in contrast
with the immunogenicity results, as higher immunogenicity was
obtained in the subjects without prior polysaccharide vaccination.
Several factors may contribute to reactogenicity, including
preexisting immunity to the meningococcal and TT antigens. Also
the sample size of the study was limited, the subjects in the MPS
group were less compliant in returning their symptom sheets, and
the observed differences may be non-relevant study ﬁndings.
Nonetheless, both vaccination regimens were associated with an
acceptable safety proﬁle, with each grade 3 solicited symptom
reported in no more than 5.5% of recipients in each treatment
group.
The study was limited by its open design, as all subjects
received the same study vaccine, and by the numerous exploratory
statistical comparisons performed with no adjustment for
multiplicity. It was recognized that any observed differences
might be due to chance and therefore must be interpreted within
the context of clinical relevance. Another limitation of this study
comes from the possible selection bias introduced into the study by
the lack of randomization and the smaller sample size in the
G. Dbaibo et al. / International Journal of Infectious Diseases 16 (2012) e608–e615e614control group. Indeed, the two groups could not be randomized as
the subjects of the MPS group were recruited amongst subjects
vaccinated in a previous study with a meningococcal polysaccha-
ride vaccine. This was mitigated by enrolling the subjects of the
control group amongst age-matched subjects coming from the
same region. Finally, longer follow-up periods could be considered
in the future, as differences in antibody titers immediately post-
vaccination may not translate into differences in long-term
antibody persistence.
In conclusion, these data support revaccination with one dose of
the MenACWY–TT conjugate vaccine following previous vaccina-
tion with the Men-PS vaccine if sustained protection against
invasive meningococcal disease is needed. MenACWY–TT induced
a robust response in subjects previously vaccinated with a plain
polysaccharide vaccine even though bactericidal antibody titers
were lower than in subjects with no meningococcal vaccination in
the past 10 years. These results suggest that the MenACWY–TT
vaccine could be considered for implementation in vaccination
programs irrespective of the pre-vaccination status with a
polysaccharide vaccine.
NimenrixTM and Mencevax1 are registered trademarks of the
GlaxoSmithKline group of companies.
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